hese are challenging times for governments, public health administrations and the financial markets. While each biopharma company’s primary concern is the health and safety of its team members
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2019 Annual Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal landscape.
Based on recent acquisition activity by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing validity.
I recently returned from a month in Europe as part of our effort to expand Locust Walk’s European practice. It was an amazing trip meeting great people and learning valuable lessons.
Special Report on the U.S. Biopharmaceuticals Industry 2019
Selected quotes from the interview with Geoff Meyerson, CEO and Co-Founder of Locust Walk
It is that time of year again when the orthopedics community comes together to reflect on the recent American Academy of Orthopedic Surgeons (AAOS) meeting which took place in Las Vegas and finished late last week.
If you are raising capital now, the path you are about to embark on can be stressful and littered with obstacles, but the light at the end of the tunnel is worth the trials and tribulations.
The JP Morgan Healthcare Conference, or “JPM”, is the healthcare conference of the year. Companies from all over the world convene in San Francisco to setup meetings with investors
A few months ago, I posted a related article about deal timing titled ‘Maintaining Deal Momentum in the Summer Months’. Now it is early August, and we are deep in the summer slowdown.
What happened to the value of priority review vouchers (PRV)? CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute